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Vascular permeability factor (VPF), also known as 
vascular endothelial growth factor (VEGF), plays an 
important role in the increased vascular permeability 
and angiogenesis associated with many malignant 
tumors. In addition, VPF/VEGF is strongly expressed 
by epidermal keratinocytes in wound healing and 
psoriasis, disorders that are also characterized by 
increased microvascular permeability and angiogen-
esis. In this study, we investigated the expression of 
VPF/VEGF in three bullous diseases with subepider-
mal blister formation that are characterized by hy-
perpermeable dermal microvessels and pronounced 
papillary dermal edema. The expression of VPFI 
VEGF mRNA was strongly up-regulated in the le-
sional epiderrtlis of bullous pemphigoid (n = 3), 
erythema multiforme (n = 3), and dermatitis herpet-
iformis (n = 4) as detected by in sit .. hybridization. 
Epidermal labeling was particularly intense over blis-
V ascular permeability factor (VPF) is a 34-42-kD homodimeric protein that induces microvascular hyperpenneability with a potency some 50,000 times that of histamine on a molar basis [1,2]. VPF is also a selective endothelial cell mitogen and is 
alternatively known as vascular endothelial growth f.1ctor (VEGF) 
[3-6] . Two high-affinity tyrosine kinase VPF/VEGF receptors, flt-1 
and KDR, have been identified and are expressed on vascular 
endothelial cells [7,8]. 
Overexpression ofVPF/VEGF and both of its receptors has been 
documented in a number of transplantable anin1al and autochro-
nous human tumors [9-15], and it is thought that VPF/VEGF plays 
an important part in the increased vascular permeability and 
angiogenesis associated with these malignancies. VPF/VEGF ex-
pression is also up-regulated as part of the angiogenic response 
accompanying corpus luteum development [16-18]. In addition, 
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te,.-s, but strong expression was also noted in areas of 
the epidermis adjacent to dermal inflammatory infil-
tr..-tes at a distance from blisters. Moreover, the 
Vl?F/VEGF receptors, flt-l and KDR, were up-regu-
lat;ed in endothelial cells in superficial dermal mi-
c .. ovessels. High levels of VPFiVEGF (138-238 pM) 
w~re detected in blister fluids obtained from five 
p~1:ients with bullous pemphigoid. Addition of blister 
Buid to human dermal microvascular endothelial 
ceJls exerted a dose-dependent mitogenic effect that 
w ... s suppressed after depletion of VPF/VEGF by im-
ru-."noadsorption. These findings strongly suggest 
tb..-t VPFiVEGF plays an important role in the induc-
tj~n of increased microvascular permeability in bul-
lo"'s diseases, leading to papillary edema and fibrin 
deposition and contributing to the bulla formation 
cb:aracteristic of these disorders. ] Invest Dermatol 
104:744-749, 1995 
VJ?:F/VEGF is overexpressed by epidermal keratinocytes in certain 
no~, -neoplastic processes of the skin that are characterized by 
increased microvascular permeability and angiogenesis; i.e., cuta-
ne()US wound healing [19] and psoriasis [20]. Expression of both 
flt-1- and KDR is also up-regulated on the elongate and dilated 
deJ't'llal papiJJary microvessels that develop in psoriatic lesions [20] . 
l-1yperperm eable dermalmicrovcssels leading to papillary dermal 
edef113 and fibrin deposition are also characteristic features of 
bullous diseases associated with subepidermal blister formation, 
e.g,. bullous pemphigoid, erythema multiforme, and dermatitis 
hetpetifonllis [21-25]. These features led us to hypothesize that 
incl:eased expression of VPF/VEGF and/or its endothelial cell 
rec~ptors might play an important role in these bullous diseases. To 
test this hypothesis, we studied the expression ofVPF/VEGF and its 
rec~ptors in the lesional skin of patients with bullous pemphigoid, 
den.,-Jatitis herpetiform is, and erythema multiforme using ill silll 
hybtidization (ISH). In addition, we m easured the concentration of 
Vp):::/VEGF protein in blister fluids of patients with bullous pem-
phi~oid and tested the capacity of such fluids to stimu.late the 
groV"th of cultured human dermal microvascular endothelial cells 
(I-IDMEC). Expression of VPF/VEGF ml~A was dramatically 
Up_l:"egulated in the lesional epidennis of all bullous disorders 
stuclicd. Moreover, high levels of bioactive VPF/VEGF were 
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Table I. Enhanced VPFIVEGF mRNA Expression in 
Bullous Diseases but Not in Acute Urticaria 
VPF mRNA 
Case Number Age Sex Site DJF" in Epidennisb 
Bullous pemphigoid 
1 98 M Thigh IgG, C3 +++ 
2 81 M Thigh JgG, C3 +++ 
3 78 F Ann NDf, 11 +++ 
Dermatitis herpetiformis 
4 25 F Buttocks IgA, IgG, C3 +++ 
5 70 M Ann JgA, C3 +++ 
6 55 M Elbow IgA, C3 +++ 
7 38 F Elbow [gA, C3 +++ 
Erythema multiforme 
8 28 M Back NO' ++ 
9 26 F Foot NO' +++ 
10 38 M Finger IgA, IgG, C3 +++ 
Urticaria 
11 39 M Arm NO' + 
12 33 F Arm NO' + 
II IgA, IgG, o r C3 at the basement membrane, as detected by direct iJnmunoEluo-
reSCCf1Cc. 
"VPF/VEGF II1RNA expression: + = weak (0-5 grains /cell) ; ++ = moderate 
(6-15 grains) ; +++ = strong (> 15 grains). 
" Not determined. 
(/ Indirect immunofluorescence on monkey esophagus substrate: circulating anti-
basement membrane zone antibodies in a titer of 1 :25. 
detected in blister fluids obtained from patients with bullous 
pemphigoid. These results suggest an important role for VPFI 
VEGF in the mediation of microvascular hyperpermeability and 
papillary dermal edema in bullous diseases. 
MATERIALS AND METHODS 
I .. Sit .. Hybridization ISH was performed on 4-!.I.m-thick sections of 
archival formalin-fixed, parall:in-embedded tissue. We studied a total of 
four cases of dermatitis herpetiformis, three cases of erythema multifortne, 
three cases of bullous pemphigoid, two cases of urticaria , and a control 
biopsy specimen of norn131 skin from a healthy volunteer (see Table I). 
Details oflSH have been published previously [26]. Briefly, the slides were 
processed through "'1'lene to remove paraffin, then passed sequenti a lly 
through graded alcohols; 0.2 M H C I; Tris/ethylenediamine tetracetic acid 
(EDTA) with 3 !.I.g/ml proteinase K; 0.2% glycine; 4% paraforma.ldehyde in 
phosphate-buffered saline, pH 7.4; 0.1 M triethanolamine containing 1/200 
(vol/vol) acetic anhydride; and 2 X sodium citrate/sodium chloride buffer 
(SSC) . Slides were hybridized overnight at 50°C with 35S-labeled ribo-
probes in the followin g mixture: 0.3 M NaC I, 0.01 M Tris pH 7.6, 5 .pM 
EDTA, 0.02% wt/vol Ficoll , 0.02% wt/vol polyvinylpyrolidone, 0.0:2% 
wt/vol bovinc serum albumin (fraction V), 50% formamide, 10% dextran 
slti£,te, 0.1 mg/ml yeast tRNA, and 0.01 M dithiothreitol. Post-hybridi:za-
tion washes included 2 X SSC/50'X, fonnamide/l0 mM dithiothreitol at 
50°C; 4 X SSCll0 mM Tris/ l mM EDT A with 20 !.I.g/ml ribonuclease at 
37°C; and 2 X SSC/50% formamide/l 0 mM dithiothreitol at 65°C and :2 X 
SSC. Slides were then dehydratcd through graded alcohols contain.ing 
0.3 M ammonium acetate, dried, coated with Kodak NTB 2 emulsion, alld 
stored in the dark at 4°C for 2 weeks. T he emulsion was dcveloped with 
Kodak 019 developer, and the slides were counterstained with hemato:;o<y-
lin. Details of the selection and preparation of the antisense, single-slnnded 
3SS-labeled VPF/VEGF RNA probe and its sense control have been 
described [27]. The antisense probe hybridizes specifically with a regiOl'l of 
VPF/VEGF mRNA common to all four VPF/VEGF splicing variants. 
Selection and preparation of 35S-labeled singlc-stranded antisense and seose 
RNA probes for the VPF/VEGF receptors f1t-l and KDR have also been 
described previously [10] . 
Quantification of VPF/VEGF mRNA Labeling Individual photo-
graphic grains were counted over epithelial keratinocytes, and biopsy 
specimens were scored as wcakJy (zero to five grains per kcratinocYl:e), 
mode.rately (six to 15 grains per keratinocyte), or strongly positive (more 
than 15 grains per kcratinocytc). Grain counts were performcd in the n,cst 
intensely labeled areas of thc epidermis. Labeling for the Vl)F/VEGF 
receptors was less intense; therefore, f1t-l and KDR overlying endothe lial 
cells were classified only as equa.l to or distinctly greater than the very low 
levels found in normal skin. 
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Table II. High Levels of VPFIVEGF in Blister Fluids 
from Bullous Pemphigoid, and Enhanced 3H_ Thymidine 
Incorporation in HDMEC After Addition of 5% Blister 
Fluid 
Case Protein DPM CH-Tdr) 
Number Age Sex (mg/ml) VPF (PM)" (Xl0-')" 
C" 50 0 2.23 :!:: 0.38 
1 73 F 57 138.0 :!:: 6.2 5.46 :!:: 0.36' 
2 82 F 47 l46.0 :!:: 5.1 6.01 :!:: 0.45' 
3 90 F NOd 190.5 :!:: 18.5 6.89 :!:: 0.78' 
4 55 F 51 216.8 :!:: 9.0 NOd 
5 73 M 61 238.8 :!:: 8.3 8.99 :!:: 1.12' 
,I Mean :!:: SO. 
b Control: 50 mg/ ml bovine serum albumin in saline. 
r Significant increase of 3H-thytnidinc incorporation in HDMEC compared with 
control (p < 0.01). 
., Not dctennillcd. 
VPFIVEGF Detection in Blister Flnids Blister fluid was obtained from 
five wltreated patients with bullous pemphigoid (see Table II) and was 
immediately stored frozen at - 80°C. The diagnosis of bullous pemphigoid 
was confinned by routine histologic evaluation and by direct immunoflu-
orescence study, which demonstrated linear deposits of IgG and C3 along 
the basement membrane in all patients. Mononuclear inflammatory infil-
trates with a considerable number of eosinophils were present in all cascs. 
The total protein concentration in blister fluids was dcternlined by the 
method of Lowry e( al [28] . VPF/VEGF was quantitated in blister fluid using 
a modification of the previ:>usly described human VPF/VEGF assay [29,30] . 
Briefly, rabbit polyclonal antibodies developed against recombinant human 
VPF/VEGF were used as both "capture" and "detection" antibodies. These 
antibodies react with VPF/ VEGF on Western blots, immulloprecipitate 
VPF/VEGF, and block the activity ofVl)F/VEGF in the Miles penneability 
assay. Affinity-purified anti-VPF/VEGF IgG was used to coat Ma..'\.;sorp 
microtiter wells (Nunc, Inc., Naperville, fL). Another aliquot of the same 
affinity-purificd anti-VPF/ VEGF IgG was labeled with Eu +++-chelate for 
use as the detection antibody. In tllC presence ofVPF/VEGF, a sandwich is 
fOrllled. Finally, Eu +++ was dissociated from the detection antibody witll an 
enhancement buffer containing B-diketone (Pharmacia LKB Nuclear, 
Gaitllersburg, MD) to produce a highly f1uoresccnt chelate, which was 
mcasured in a time-resolved fluorimeter. Human recombina.nt VPF/VEGF 
(R&D Systems, Minneapolis, MN) was nsed to calibrate the assay. 
Mitogenic Activity of Blister Fluids on HDMEC Blister fluid was 
also tested for its capacity to stimulate the growth of HDMEC. HDMEC 
were isolated frOll1 neona tal foreskins after routine circunlcisions and 
propagated as described [31). Fifth-passage HDMEC were seeded at 5 X 10' 
ceIJs/cm 2 in 24-well tissue cu.lture clusters (Costar, Cambridge. MA) in 
£EM medium (Clonetics, San Diego, CAl supplemented with 2% fetal 
bovine serum and antibiotics. After 16 h , blister fluids (or, as a control, 
salinc solution containing 50 mg/ ml bovine serum albumin) were added to 
a final volumc of 5%. Mter 48 h of additional culture, mctllyH' H] 
thymidine (specific activity 82.4 C i/mmol; DuPont NEN, Boston, MA) was 
added (1 !.I.Ci/ well) for a final 6 h; tllynlidine incorporation into DNA was 
then detennined as described [32J. Data are expressed as DPM/well (mean 
:!:: SO, n = 4). Statistical significance was calculated ,vith tile Dunnett 
multiple comparison test. 
To detenrune whether mitogenic activity present in blister fluid was 
attributable to VPF/VEGF, wc depleted VPF/VEGF from the blister fluid of 
case 1 (see Table II) by solid-phase immunoadsorption [33], using an 
affinity-purified rabbit antibody against a 26-amino-acid peptide corre-
sponding to the NH2-terminus of human VPF/VEGF coupled to protein 
A-Sepharose beads (Phamlacia , Uppsa.la, Swedcn). T he speci~city of tlus 
antibody has been documented by Western blotting [33]. T he anti-VPFI 
VEGF antibodies did not bind to recombinant human platelet-derived 
growth factor AJ3 at any of tile concentrations tested (up to 10 !.I.g/ ml 
platelet-derivcd growth factor). ImmwlOadsorption removed more than 
95% of immunoreactive VPF/ VEGF; by contrast, passage of blister fluid 
over unconjugated protein A-Sepharose beads did not diminish VPF/ VEGF 
contcnt. The capacity of these blister fluids (10% v / v) to stimulate HDMEC 
thymidine incorporation was measurcd as dcscribed above. 
746 B1~OWN ET AL 
Figure 1. VPFNEGF is weakly expressed in normal skin. Bright-
field (A) and corresponding dark-field (B) photomicrographs of ISH in 
nonnal skin, showing very weak epithelial labeling for VPF/VEGF mRNA. 
A,B, X 288 . 
RESULTS 
Increased Expression of VPF/VEGF and Its Receptors in 
Bullous Skin Diseases A control biopsy specim en of normal 
skin from a healthy volw1teer showed only very weak labeling of 
epidennal keratinocytes for VPF/VEGF mRNA (Fig 1). Previous 
ISH studies have also shown that the epidermal keratinocytes of 
normal adult skin express VPF/VEGF mRNA only focally and at 
low levels, and dermal endothelial cells express little or no mRNA 
encoding either VPF/VEGF receptor, even when experiments were 
performed under conditions of optimal mRNA preservation 
[19,20]. In contrast, VPF/VEGF mRNA was strongly expressed, at 
least focally, by the epidermis in all three patients we studied who 
had bullous pemphigoid (Table I) . Epidermal labeling was partic-
ularly intense over blisters (Fig 2C,F) and at their edges (Fig 
2B,E), but strong expression was also noted in areas of the 
epidennis adjacent to derm al inflammatory infi ltrates at a distance 
from blisters (Fig 2A,D). VPF/VEGF expression was most prom-
inent in the supra basal layers of the epidermis. R are mononuclear 
inflammatory cells, judged to be macrophages by light microscopic 
criteria, labeled weakly for VPF/VEGF mRNA, but the vast 
majority of specific VPF/VEGF m essage was localized to epidern1al 
keratinocytes . In addition , distinct labeling of activated endothelial 
cells in papillary dermal microvessels was noted focally for the 
mRNAs encoding both of the VPF/VEGF receptors, flt-1 (Fig 
3A,B) and KDR (Fig 3C,D). 
VPF/VEGF mRNA expression was also up-regulated in all three 
cases of erythema multifonne studied. In two cases with prominent 
inflammation and bUster fonnation, the epidennis was intensely 
labeled. As in bullo us pemphigoid, labe ling was patchy; it was 
particularly intense at the edges of and over blisters , but strong 
labeling was also present in the epidermis in areas of inflammatory 
cell infiltration distant from blisters (Fig 4A,E) . In areas with less 
inflammation, as in relatively normal skin at the edges of specimens, 
labeling was less intense (Fig 4B,F) . Again as in bullous pemphi-
goid, VPF/VEGF mRNA expression was most prominent in the 
supra basal layers of the epidern1is. Occasional mononuclear inflam-
matory cells, most likely macrophages, labeled weakly for VPFI 
VEGF mRNA. Our third patient exhibited much less inflammation 
and no blister form ation, and specim ens labeled with only moderate 
intensity for VPF/VEGF mRNA. Activated endothelial cells in 
some papillary dermal microvessels that were cuffed by inflamma-
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Figure 2. VPF/VEGF is strongly expressed in bullous pempWgoid. 
Bright-field (A,B,C) and corresponding dark-fi eld (D, E,F) photomicro-
graphs of ISH in bullous pemphigoid. A,D) Strong epithelial labeliug for 
VPF/VEGF mRNA in a lesion without bulla; B,b, strong epithelial labeling 
for VPF/VEGF at the edge of a bulla ; C,F) strong epithelial labeling 
overlying a bulla (b) . A -F, X 288 . 
tory cells labeled distinctly for mRNAs encoding botl1 VPF/VEGF 
receptors (not illustrated) . 
In aU four cases of demlatitis herpetiformis studied, VPF/VEGF 
mRNA was strongly expressed in the epidermis imn1ediately 
overlying subepidermal collections of neutrophils (Fig 4C,G). 
Labeling was strongest in the suprabasallayers of the epidermis . No 
unequivocal labeling for VPF/VEGF mRNA was detected in the 
inflammatory ceU infiltrates, which were composed predominantly 
of n eutrophils. As in the other bullous diseases, no specific labeling 
was seen with the control sense probe, and background levels w ere 
low (Fig 4D,H). Distinct labeling for both flt-1 and KDR mRNAs 
was detected in endothelial cells of at least some superficial vessels 
in three of the four cases studied. 
In contrast to bullous skin diseases, the two cases of urticaria 
showed only weak epidern1al labeling for VPF/VEGF mRNA, 
comparable to the labeling found in normal skin. Inflammatory 
changes were mild in these two cases, but rare mononuclear 
inflammatory cells did label weakly for VPF/VEGF mRNA. Weak 
endothelial cell labeling for VPF/VEGF receptor ml'tNAs was 
found in one case. 
Bioactive VPF/VEGF Is Present at High Levels in Blister 
Fluids of Bullous Pemphigoid Blister fluids obtained from fiv e 
previously untreated patients with bullous pemphigoid were sub-
j ected to immunoassay. High levels ofVPF/VEGF w ere detected in 
all bUster fluids (Table II), ranging from 138 to 238 pM (approx-
in1ately 5.5 to 10 ng/ml). Although the total protein content of the 
bUster fluid s studied (Table II) approximates the total prote in 
concentration in normal serum , serum from patient 1 was available 
for study and was found to contain only 7.6 pM VPF/VEGF, 
approxim ately 20 times less VPF/VEGF than the blister fluid level. 
Together with the demonstration of marked overexpression of 
VPF/VEGF by epidermal keratinocytes adjacent to blisters, these 
data sugges t that the VPF/VEGF present in bliste r fluid is syntlle-
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Figure 3. VPF/VEGF receptors are strongly expressed in bullous 
pemphigoid. Bright-field (A,C) and correspondjng da.rk-field (B,D) pho-
tomicrographs of ISH in bullous pemphigoid. Endothelial cells in papilla.ry 
de rmal vessels (D, IIIltite anollls) label distinctly for ml~As of tile VPF 
receptors flt-l (A ,B) and KDR. (C,D). A,D, X 144. 
sized locally and does not merely reflect nonspecific leakage of 
VPF/VEGF from the serum into blister fluid. 
To determine whether immuJl0reactive VPF/VEGF in blister 
fluid was biologically active, we examined the capacity of blister 
fluids to enhance the proliferation of HDMEC ill vitro. Addition of 
blister fluids to HDMEC cultured in basal medium exerted a 
significant and dose-dependent mitogenic effect (Table II). Suffi-
cient blister fluid was available from patient 1 to determine whether 
depletion of VPF/VEGF by affinity chromatography removed 
endothelial cell mitogenic activity. In fact, depletion ofVPF/VEGF 
by specific immunoadsorption removed approximately 95% of 
VPF/VEGF antigen and also suppressed the mitogenic effect of 
blister fluid on HDMEC by approxinlately 78'Vo . 
DISCUSSION 
The data presented here indicate that VPF/VEGF is strongly 
overexpressed by supra basal epidermal keratinocytes in bullous 
pemphigoid, erythema multifon11e, and dermatitis herpetiformis, 
three skin disorders characterized by vascular hyperpermeability, 
papillary dermal edema, and subepidermal bulla formation. Mark-
edly increased expression of VPF/VEGF mRNA was detected 
consistently in the immediate vicinity of bullae. VPF/VEGF was 
also overexpressed in areas of epidermis that lacked bullae but that 
overlay accumulations of inflammatory cells; therefore, keratino-
cyte overexpression of VPF/VEGF can precede the appearance of 
bullae and may contribute to their formation. In contrast, normal or 
relatively normal epidermis at the edges of some biopsy specimens 
that was not associated with underlying inflammatory cells ex-
pressed little or no VPF/VEGF mRNA, and in this respect resem-
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Figure 4 . VPFIVEGF is strongly expressed in erythema multiforme 
and dermatitis herpetiformis. Bright-field (A-D) and corresponding 
dark-field (E-H) photomicrographs oflSH. A,B) Erythema multifonne Witll 
strong epithelial labeling for VPF/ VEGF mRNA in a heavily inflamed area; 
B,F) erythema multiforme with weak epithelial labeling at the relatively 
1I11infiamed edge of the sam e biopsy specimen; C,G) demlatitis herpe tifor-
mis with strong epithelial labeling for VPF/VEGF ml~A djrectly overlying 
a papillary demlal collection of ncutrophils (C, atwllliteads); D ,H) dennatiti s 
herpetiformis with no specific labeling willi sense control. A-H, X 288. 
bled the epidermis of norma.l skin . Rare infiltratiJlg mononuclear 
inflammatory cells, presumably macrophages, also expressed easily 
detectable levels of VPF/VEGF mRNA, but the vast majority of 
VPF/VEGF message was localized to epidennal keratinocytes. 
Normal human skin expresses little or no mRNA of either 
VPF/VEGF receptor as judged by ISH [20). However, substantial 
amounts of both flt-l and KDR ml~As were expressed by the 
activated endothelial cells of the superficial dermal microvessels 
associated with bullous pemphigoid, den1latitis herpetifonnis, and 
erythem a multiforme, particula.r1y when these vessels were cuffed 
by mononuclear inflamll1atory cells. Taken together, overexpres-
sion ofVPF/VEGF and of its two endothelial cell receptors suggests 
that VPF/VEGF has an important role in the increased vascular 
permeability and resulting edema, fibrin deposition, and bullae 
formation characteristic of all t11ree skin disorders. VPF/VEGF may 
also playa role in later phases of these diseases in which areas of 
ulceration develop and undergo healing with concomitant angio-
genesis. 
In contrast, in both cases of urticaria studied, epidermal VPFI 
VEGF mRNA levels were not increased above the background 
levels of normal skin , and only weak expression was detected in 
rare mononuclear inflammatory cells . These data suggest that 
VPF/VEGF is not the major mediator of the edema in acute 
urticaria, which is thought to be mediated by mast cell products 
such as histamine [34). However, the levels of inflammation in the 
two cases of urticaria we studied were relatively mild, and it is 
possible that more intense expression ofVP.F/VEGF ml~A would 
be found in cases with more extensive inflammatory changes. 
ISH was performed entirely on archival paraffm-embedded tis-
sue. T hus, different specimens were fixed for variable times, and no 
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special precautions were taken to avoid exposure to RNAse during 
processing. It has been our experience that ISH results are substan-
tially more intense on optimally prepared, fixed-frozen sections. 
Thus, although the results in tlus study are consistent in demon-
strating significantly increased VPF/VEGF and VPF/VEGF recep-
tor mRNAs in several bullous skin disorders, they almost certainly 
underestimate the actual levels of expression. 
Consistent with our findings of increased VPF/VEGF expression 
in bullous pemplugoid, blister fluids obtained from five patients 
contained substantial amounts of immunoreactive VPF/VEGF 
(138-238 pM). These levels are impressive because the lughest 
level that we found in a study of human malignant tumor effusions 
was 132 pM [30]. To detennine whether the VPF/VEGF antigen 
that we detected by immunoassay was biologically active, we 
measured the effect of blister fluid on the DNA synthesis of 
HDMEC. Blister fluid (final concentration 5% to 10%) significantly 
stimulated HDMEC proliferation in all four cases studied. More-
over, when VPF/VEGF was selectively depleted by immunoad-
sorption, its niltogenicity was largely lost. These findings provide 
strong evidence that bullous pemplugoid epidem~is expresses VPFI 
VEGF mRNA and secretes bioactive protein in amounts that are 
sufficient to exert potent biologic effects on local blood vessels. 
VPF/VEGF may account for much of the vascular hyperpermeabil-
ity and angiogenesis associated with bullous pemplugoid, but we 
carmot exclude the possibility that other unidentified factors could 
also playa role. 
We are only beginning to understand the factors that control 
VPF/VEGF expression. Hypoxia has been shown to up-regulate 
VPF/VEGF mRNA expression in certain cells il'l vitro [35,36], 
including keratinocytes (M. Detmar et ai, manuscript submitted for 
pubUcation), and may playa role in the up-regulated expression of 
VPF/VEGF in cutaneous wound healing. Although oxygen con-
centrations have not been measured directly in bullous disorders, 
the increase ofVPF/VEGF expression in epidermis separated from 
dennis by blister fluid nilght be explained in part by tissue hypoxia 
due to the increased distance between the keratinocytes and the 
supplying dennal blood vessels. 
In addition, we recently reported that transforming growth 
factor-a potently up-regulates VPF/VEGF mRNA in cultured 
keratinocytes [20] and by this mechanism likely contributes to the 
increased expression of VPF/VEGF found in psoriasis and in 
healing wounds, which have been associated with keratinocyte 
overexpression of transfonning growth factor-a and its receptor 
(the epidennal growth factor receptor) [37-39]. However, to our 
knowledge, transforming growth factor-a expression in bullous 
skin diseases remains to be investigated. The strong expression of 
VPF/VEGF in epidermis adjacent to inflammatory infiltrates away 
from bUsters suggests that additional factors that enhance the 
expression ofVPF/VEGF may be released from inflammatory cells. 
In summary, VPF/VEGF mRNA is strongly expressed by epi-
dermal keratinocytes in dennatitis herpetiformis, bullous pemplu-
goid, and erythema multiforme. In addition, the mRNAs of the 
VPF/VEGF receptors f1t-1 and KDR are overexpressed by acti-
vated endothelial cells in papillary dermal microvessels in these 
lesions. These findings, together with the high levels of bioactive 
VPF/VEGF in blister fluids from bullous pemphigoid, strongly 
suggest that VPF/VEGF plays an important role in the increased 
microvascular permeability and resulting edema, fibrin deposition, 
and bulla formation characteristic of these diseases. 
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